A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.
about
Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspectiveVaccination against herpes zoster in developed countries: state of the evidenceHerpes zoster vaccine (Zostavax®): Cellulitic injection site reaction or bacterial cellulitis?Compliance with herpes zoster vaccination in young and adult individuals in two regions of ItalyCost-effectiveness of vaccination against herpes zoster.Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the Zoster Quality of Life (ZQOL) study.Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.The humanistic, economic and societal burden of herpes zoster in Europe: a critical reviewEconomic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in GermanyA systematic review of the cost effectiveness of herpes zoster vaccination.Persistent dilemmas in zoster eye disease.Herpes zoster vaccine: A health economic evaluation for Switzerland.COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.Clinical and economic impact of herpes zoster vaccination in elderly in Italy.Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
P2860
Q26781940-20B626A4-39FE-4FE6-AB71-3185E3ACDCCAQ26862748-AB77DC97-EBFA-4681-8808-789ED492F8C7Q33601337-B8914C4B-F4D6-42E8-AFBF-89469A0A82C5Q33602005-23DF3985-7AA1-41E3-B9C7-119F6ABB1FCDQ34291150-C6BB73CB-6D56-4414-BC31-97EF94F993BAQ34461800-C548E883-1437-4269-A464-05E35D72081BQ35000186-20C1C5C7-B458-40F2-8715-C4BD976DBE2DQ35147612-9A78C28B-8C9E-44C8-96DE-928770EFB2F4Q35558544-F3D3CA97-C51F-42EE-8F72-E559B9FCE0ADQ35652212-B055FBB2-1A72-439C-BC97-7051C00E1E98Q35887517-B3BCACDA-5784-45B4-BC84-36A94638E83EQ38075493-1A02FA59-E736-45BD-BEBE-1E4FBD66B9C3Q38475791-682794BE-EF91-4F65-83BC-C76B22F4AB9FQ38798312-27E370B8-9623-4D86-B4FA-61D4A2AD9A8DQ39394780-0A020E0B-3715-4560-AF2C-73A1E4D76C16Q45937750-44BFFCBF-E00A-458F-BE64-B1D4E622789DQ46941948-AF90A9D5-4436-483A-AF82-40A316FE965F
P2860
A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A health economic model for ev ...... -herpetic neuralgia in the UK.
@ast
A health economic model for ev ...... -herpetic neuralgia in the UK.
@en
type
label
A health economic model for ev ...... -herpetic neuralgia in the UK.
@ast
A health economic model for ev ...... -herpetic neuralgia in the UK.
@en
prefLabel
A health economic model for ev ...... -herpetic neuralgia in the UK.
@ast
A health economic model for ev ...... -herpetic neuralgia in the UK.
@en
P2093
P2860
P356
P1476
A health economic model for ev ...... -herpetic neuralgia in the UK.
@en
P2093
Maud Beillat
Monique Martin
Vanessa Remy
P2860
P2888
P356
10.1186/1478-7547-8-7
P577
2010-04-30T00:00:00Z